» Articles » PMID: 19384426

The Phosphoinositide 3-kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications

Overview
Journal Curr Genomics
Date 2009 Apr 23
PMID 19384426
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in human cancer and represents an attractive target for therapies based on small molecule inhibitors. PI3K isoforms play an essential role in the signal transduction events activated by cell surface receptors including receptor tyrosine kinases (RTKs) and G-protein-coupled receptors (GPCRs). There are eight known PI3K isoforms in humans, which have been subdivided into three classes (I-III). Therefore PI3Ks show considerable diversity and it remains unclear which kinases in this family should be targeted in cancer. The class I(A) of PI3K comprises the p110alpha, p110beta and p110delta isoforms, which associate with activated RTKs. In human cancer, recent reports have described activating mutations in the PIK3CA gene encoding p110alpha, and inactivating mutations in the phosphatase and tensin homologue (PTEN) gene, a tumour suppressor and antagonist of the PI3K pathway. The PIK3CA mutations described in cancer constitutively activate p110alpha and, when expressed in cells drive oncogenic transformation. Moreover, these mutations cause the constitutive activation of downstream signaling molecules such as Akt/protein kinase B (PKB), mammalian target of rapamycin (mTOR) and ribosomal protein S6 kinase (S6K) that is commonly observed in cancer cells. In addition to p110alpha, the other isoforms of the PI3K family may also play a role in human cancer, although their individual functions remain to be precisely identified. In this review we will discuss the evidence implicating individual PI3K isoforms in human cancer and their potential as drug targets in this context.

Citing Articles

Evaluation of PI3K Levels and miRNA124-5p Expression Levels in Serum Samples from Patients With Lung Cancer.

Akdeniz F, Avsar O Cancer Diagn Progn. 2025; 5(2):223-229.

PMID: 40034961 PMC: 11871863. DOI: 10.21873/cdp.10433.


Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer.

Fatima S, Kumar V, Kumar D Med Oncol. 2025; 42(3):61.

PMID: 39893601 DOI: 10.1007/s12032-025-02608-5.


Unraveling the role of LncRNAs in glioblastoma progression: insights into signaling pathways and therapeutic potential.

Doghish A, Abd-Elmawla M, Hatawsh A, Zaki M, Aborehab N, Radwan A Metab Brain Dis. 2024; 40(1):42.

PMID: 39589598 DOI: 10.1007/s11011-024-01456-y.


Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors.

Poustforoosh A Mol Biotechnol. 2024; .

PMID: 39463205 DOI: 10.1007/s12033-024-01307-2.


Herbal Remedies for Hepatic Inflammation: Unravelling Pathways and Mechanisms for Therapeutic Intervention.

Saraswat I, Goel A Curr Pharm Des. 2024; 31(2):128-139.

PMID: 39350422 DOI: 10.2174/0113816128348771240925100639.


References
1.
del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997; 278(5338):687-9. DOI: 10.1126/science.278.5338.687. View

2.
Price B, Youmell M . The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. 1996; 56(2):246-50. View

3.
Graziani A, Gramaglia D, Cantley L, Comoglio P . The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem. 1991; 266(33):22087-90. View

4.
Isakoff S, Cardozo T, ANDREEV J, Li Z, Ferguson K, Abagyan R . Identification and analysis of PH domain-containing targets of phosphatidylinositol 3-kinase using a novel in vivo assay in yeast. EMBO J. 1998; 17(18):5374-87. PMC: 1170863. DOI: 10.1093/emboj/17.18.5374. View

5.
WALKER E, Pacold M, Perisic O, Stephens L, Hawkins P, Wymann M . Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell. 2000; 6(4):909-19. DOI: 10.1016/s1097-2765(05)00089-4. View